Roche and Nurix Therapeutics Sign $2.3 Billion Deal to Co-Develop Bexobrutideg

Deal Structure and Financial Terms

The financial framework of the agreement is designed to share risk and reward equally between the two companies in the U.S. market, while leveraging Roche's international infrastructure for global sales.

• Upfront Payment: Nurix will receive a cash payment of $700 million from Roche upon closing .
• Total Value: Including development, regulatory, and sales milestone payments, the deal's total potential value reaches up to $2.3 billion .
• Development Costs: Future development expenses will be shared, with Nurix covering 40% and Roche covering 60% .
• U.S. Profit Split: Commercial profits and losses in the United States will be divided equally (50/50) .
• Ex-U.S. Commercialization: Roche will lead commercialization outside the United States, where Nurix will be eligible for tiered royalties ranging from low-teens to high-teens on net sales .

The Science: Destroying BTK, Not Just Blocking It

Bexobrutideg represents a significant shift in strategy for targeting BTK. Conventional drugs like ibrutinib and pirtobrutinib are kinase inhibitors that bind to BTK and block its enzymatic activity. However, BTK also serves a "scaffolding" function, acting as a physical platform for other signaling proteins, which is not disrupted by inhibitors. Cancer cells can also mutate the BTK protein, preventing the drugs from binding effectively .

Bexobrutideg works as a degrader. It tags the BTK protein for disposal by the cell’s own waste-disposal system, the ubiquitin-proteasome pathway. Specifically, it recruits the cereblon E3 ubiquitin ligase complex to BTK, leading to the protein's full destruction . This approach eliminates both the enzyme’s catalytic and scaffolding functions .

This mechanism is particularly promising against drug-resistant cancers. Preclinical and clinical data have shown that bexobrutideg is active against wild-type BTK and a range of resistance mutations, including the common C481S mutation that renders covalent BTK inhibitors ineffective . Clinical findings from a Phase 1 trial presented at major hematology conferences have demonstrated durable responses in heavily pretreated CLL patients regardless of their BTK mutation status .

Clinical Development Strategy and Market Opportunity

The development plan is aggressive, targeting multiple disease areas. The immediate priority is validating the drug in B-cell malignancies.

The foundational Phase 1 trial (NX-5948-301) in relapsed/refractory CLL has shown rapid and durable clinical responses, even in patients with central nervous system involvement or those double-refractory to both BTK inhibitors and venetoclax . Building on this, a pivotal Phase 3 trial for second-line CLL is planned to begin in the summer of 2026 .

The collaboration's scope extends into immunology and neurology, with plans to initiate Phase 2 clinical trials in multiple sclerosis and chronic spontaneous urticaria . This broad vision is backed by a substantial market opportunity. The combined market for non-Hodgkin lymphoma and CLL is projected to reach $41 billion by 2031, with BTK inhibitor therapies expected to account for roughly $19 billion of that total .

Executive Perspectives and Next Steps

Leaders from both companies emphasized the potential of combining their expertise to bring a new class of medicine to patients.

Levi Garraway, Roche's Chief Medical Officer, stated, "We believe bexobrutideg could represent a major leap forward in the fight against complex blood cancers and other diseases. We are proud to join forces with Nurix to accelerate these potential breakthroughs" .

Arthur T. Sands, President and CEO of Nurix, added, "We believe Roche is the ideal partner to help translate the promise of targeted protein degradation into meaningful impact for patients worldwide... We can now rapidly expand our Phase 3 program enhanced by Roche's global reach" .

The transaction is expected to close in the third quarter of 2026, subject to customary closing conditions and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act .